Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
baxter.com

See what CB Insights has to offer

Investments

9

Portfolio Exits

3

Partners & Customers

10

Service Providers

1

About Baxter International

Baxter International (NYSE: BAX) is an American healthcare company that provides a broad portfolio of essential renal and hospital products, including home, acute, and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software, and services. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions.

Baxter International Headquarter Location

One Baxter Parkway

Deerfield, Illinois, 60015,

United States

224-948-200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Baxter International

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Baxter International in 4 Expert Collections, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

P

Pharma Supply Chain

1,258 items

C

Conference Exhibitors

5,302 items

M

Medical Devices

478 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Baxter International Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Baxter International Rank

Latest Baxter International News

Dialysis Devices And Equipment Global Market Report 2022

May 13, 2022

Major players in the dialysis devices and equipment market are Fresenius Medical Care AG & Co KGaA, Baxter International, Nikkiso Co. Ltd, DaVita Inc, B. Braun Avitum AG, NxStage Medical, Asahi Kasei Corporation, Diaverum Deutschland GmbH, Medivators Inc, and Nipro Corporation. May 13, 2022 07:24 ET Lyon, FRANCE New York, May 13, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Dialysis Devices And Equipment Global Market Report 2022" - https://www.reportlinker.com/p06277198/?utm_source=GNW The global dialysis devices and equipment market is expected to grow from $4.37 billion in 2021 to $4.7 billion in 2022 at a compound annual growth rate (CAGR) of 7.7%. The market is expected to grow to $6 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The dialysis devices and equipment market consist of the sale of dialysis devices and equipment-related services.Dialysis devices and equipment are used in the dialysis process to filter the patient’s blood, to remove waste products such as urea, creatinine, and excess water, such impurities usually occur when the kidneys fail or are damaged. Companies in this industry primarily engage in the production of dialyzers and dialysis pumping machines but can also produce other instruments used in the dialysis process, including blood pumps, catheters, and tubing kits. The main products of dialysis devices and equipment are hemodialysis devices and peritoneal dialysis devices.Hemodialysis is a process where a dialysis machine and a special filter called an artificial kidney, or a dialyzer, are used to clean the blood. The various applications involved are serum and blood treatment, virus purification, drug binding studies, and others. The various end-users are hospitals, clinics, ambulatory surgical centers, and home care settings. Asia Pacific was the largest region in the dialysis devices and equipment market in 2021.North America was the second largest market in dialysis devices and equipment market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The increasing prevalence of kidney failure is driving the market for dialysis devices and equipment.The main purpose of dialysis devices and equipment is to artificially filter the blood to get rid of any toxins in the blood and to prevent such waste products from reaching hazardous levels. Chronic kidney disease (CKD) is a condition in which the kidneys are damaged and cannot filter the blood. According to the National kidney report, 2019, 30 million Americans are affected by CKD, and 90% of people are unaware. 1 in 3 Americans run the risk of being diagnosed with CKD. In the USA, kidney disease is the 9th leading cause of death. Product recalls have been the major restraint in the dialysis devices and equipment market.Product recalls are actions taken by organizations or any regulatory authority like US FDA to remove a product or device from the market. The dialysis devices and equipment are removed from the market when they fail to perform the functions for which they were manufactured.For example, B. Braun Medical Inc. recalls Dialog hemodialysis systems due to defective conductivity sensors. This machine is used in the treatment of chronic kidney disease for patients whose kidneys are no longer healthy enough to filter the blood to get rid of the wastes and excess fluid. Similarly, the Dialyzer, a device by the Fresenius Medical Care group was recalled due to the invalid message shown on the equipment when the Sustained low-efficiency Dialysis (SLED) program is used. The latest trend in the dialysis devices and equipment market is the use of technology to develop innovative products that can enhance functionality.To enhance the quality of the devices, new methods are being developed to speed up the process of filtering the blood and improve the overall filtration process. As a result of improved technology products like Revaclear High-Flux Dialyzer by Baxter, which enhances the filtration process of the blood by improving the speed at which the blood is filtered are being developed.Revaclear dialyzers are devices that can help detect renal failure by hemodialysis. With the improvement in technology, innovations in the devices are expected to continue. In January 2019, a wearable, portable peritoneal dialysis device manufactured by Singapore-based AWAK Technologies received FDA’s breakthrough device designation to be used by end-stage renal disease patients.According to the clinical trial of the AWAK Peritoneal Dialysis device conducted at Singapore General Hospital, the device efficiently removed the accumulation of toxins from the body. Such approvals by FDA positively impact the global dialysis devices market. B.Braun completed the acquisition of NxStage’s Bloodlines business in February 2019 for $2 billion. This acquisition will help improve the quality of B Braun’s hemodialysis system and would also enhance its portfolio of bloodline business which would help in strengthening the company’s position in the market. NxStage Medical, Inc. is involved in the manufacturing of dialysis devices used for the treatment of end-stage renal disease (ESRD). One Cycle, PureFlow SL, and Nx2me Connected Health are the company’s various products. It was founded in 1998 and is headquartered in Maddison, USA. The countries covered in the dialysis devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia.

Baxter International Investments

9 Investments

Baxter International has made 9 investments. Their latest investment was in NovaXS Biotech as part of their Seed VC on March 3, 2022.

CBI Logo

Baxter International Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/31/2022

Seed VC

NovaXS Biotech

$1.5M

Yes

1

1/10/2022

Series D

Subscribe to see more

$99M

Subscribe to see more

10

5/1/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

5/23/2017

Series C

Subscribe to see more

$99M

Subscribe to see more

10

1/6/2013

Corporate Minority

Subscribe to see more

Subscribe to see more

10

Date

3/31/2022

1/10/2022

5/1/2020

5/23/2017

1/6/2013

Round

Seed VC

Series D

Series B

Series C

Corporate Minority

Company

NovaXS Biotech

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$1.5M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Baxter International Portfolio Exits

3 Portfolio Exits

Baxter International has 3 portfolio exits. Their latest portfolio exit was Baxter International - Aquadex on August 08, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/8/2016

Divestiture

$99M

4

7/25/2013

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/31/2013

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/8/2016

7/25/2013

1/31/2013

Exit

Divestiture

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

10

10

Baxter International Acquisitions

19 Acquisitions

Baxter International acquired 19 companies. Their latest acquisition was Hillrom Holdings on December 13, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/13/2021

$99M

Acq - P2P

4

6/17/2020

Convertible Note

$99M

$12.22M

Acquired

1

12/2/2019

$99M

Acquired

2

9/10/2019

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

10

1/22/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/13/2021

6/17/2020

12/2/2019

9/10/2019

1/22/2019

Investment Stage

Convertible Note

Debt

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$12.22M

$99M

Note

Acq - P2P

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

4

1

2

10

10

Baxter International Partners & Customers

10 Partners and customers

Baxter International has 10 strategic partners and customers. Baxter International recently partnered with Cybersecurity and Infrastructure Security Agency on February 2, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

2/23/2022

Partner

United States

1

10/21/2021

Partner

France

Baxter And BioMérieux Announce CE Mark For NEPHROCLEAR™ CCL14 Test To Predict Persistent Severe Acute Kidney Injury

Baxter International Inc. and bioMérieux previously announced an agreement to develop and distribute this novel AKI biomarker test to assess the risk of PS-AKI and support clinical decision-making in AKI management .

4

8/18/2021

Partner

United States

The Baxter International Foundation and UNICEF USA Announce Partnership to Improve Water Security in Colombia

`` In support of Baxter International Inc. 's mission to save and sustain lives , we are proud to expand our investment in water initiatives through a partnership with UNICEF that will support the health of communities in need . ''

3

8/3/2021

Vendor

United States

Subscribe to see more

Subscribe to see more

10

3/8/2021

Client

United States

Subscribe to see more

Subscribe to see more

10

Date

2/23/2022

10/21/2021

8/18/2021

8/3/2021

3/8/2021

Type

Partner

Partner

Partner

Vendor

Client

Business Partner

Country

United States

France

United States

United States

United States

News Snippet

Baxter And BioMérieux Announce CE Mark For NEPHROCLEAR™ CCL14 Test To Predict Persistent Severe Acute Kidney Injury

Baxter International Inc. and bioMérieux previously announced an agreement to develop and distribute this novel AKI biomarker test to assess the risk of PS-AKI and support clinical decision-making in AKI management .

The Baxter International Foundation and UNICEF USA Announce Partnership to Improve Water Security in Colombia

`` In support of Baxter International Inc. 's mission to save and sustain lives , we are proud to expand our investment in water initiatives through a partnership with UNICEF that will support the health of communities in need . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

4

3

10

10

Baxter International Service Providers

1 Service Provider

Baxter International has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired Unit

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired Unit

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Baxter International Team

37 Team Members

Baxter International has 37 team members, including current President, Wil Boren.

Name

Work History

Title

Status

Wil Boren

President

Current

Talvis Love

Chief Information Officer, Senior Vice President

Current

Jackie Kunzler

Senior Vice President

Current

Rick Adam

President, Chief Information Officer

Former

Peter J Arduini

President

Former

Name

Wil Boren

Talvis Love

Jackie Kunzler

Rick Adam

Peter J Arduini

Work History

Title

President

Chief Information Officer, Senior Vice President

Senior Vice President

President, Chief Information Officer

President

Status

Current

Current

Current

Former

Former

You May Also Like

Octapharma Logo
Octapharma

Octapharma is a provider of health solutions and human protein manufacturer, developing and producing human proteins from human plasma and human cell lines.

Ferring Pharmaceuticals Logo
Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group. Ferring Pharmaceuticals specializes in the areas of reproductive medicine and women’s health, urology and gastroenterology.

B
Biogen IDEC

Biogen (NASDAQ: BIIB) is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.